<DOC>
	<DOCNO>NCT01395017</DOCNO>
	<brief_summary>The purpose study determine whether patient locally advanced pancreatic cancer receive dasatinib add standard care ( gemcitabine ) live longer , compare patient receive standard care ( gemcitabine ) plus placebo ; i.e . gemcitabine alone .</brief_summary>
	<brief_title>Dasatinib Added Gemcitabine Subjects With Locally-advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologic cytologic documentation unresectable adenocarcinoma pancreas . Recovery toxicity previous procedure establish diagnosis . ECOG PS 0 1 . Adequate organ function . Evidence metastatic disease . Previous radiotherapy chemoradiotherapy . History current pleural effusion . History significant cardiovascular disease . Clinically significant bleed disorder coagulopathy . Concomitant medication strong CYP 3A4 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Locally advanced</keyword>
</DOC>